BRPI0408774A - vacinas de dna contra crescimento tumoral e seus usos - Google Patents

vacinas de dna contra crescimento tumoral e seus usos

Info

Publication number
BRPI0408774A
BRPI0408774A BRPI0408774-7A BRPI0408774A BRPI0408774A BR PI0408774 A BRPI0408774 A BR PI0408774A BR PI0408774 A BRPI0408774 A BR PI0408774A BR PI0408774 A BRPI0408774 A BR PI0408774A
Authority
BR
Brazil
Prior art keywords
human
tumor growth
protein
cancer
dna
Prior art date
Application number
BRPI0408774-7A
Other languages
English (en)
Inventor
Rong Xiang
He Zhou
Ralph A Reisfeld
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BRPI0408774A publication Critical patent/BRPI0408774A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

"VACINAS DE DNA CONTRA CRESCIMENTO TUMORAL E SEUS USOS". Uma vacina de DNA adequada para despertar uma resposta imune contra células cancerosas compreende uma construção de DNA que codifica operacionalmente uma proteína da família de inibidor de apoptose associado a câncer e um produto de gene imunoativo, como uma citocina ou um ligante para um receptor natural de superfície de célula assassina, em um veículo farmaceuticamente aceitável. Uma citocina preferida é CCL21. Ligantes preferidos para um receptor natural de superfície de célula assassina incluem MICA humana, MICB humana, ULBP1 humana, ULBP2 humana, e ULBP3 humana. A proteína da família de inibidor de apoptose associado a câncer (IAP) é preferivelmente uma proteína sobrevivente ou proteína viva. Também é descrito um método de inibição de crescimento tumoral pela administração da vacina da invenção a um mamífero.
BRPI0408774-7A 2003-03-24 2004-03-24 vacinas de dna contra crescimento tumoral e seus usos BRPI0408774A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45700903P 2003-03-24 2003-03-24
PCT/US2004/008932 WO2004099389A2 (en) 2003-03-24 2004-03-24 Dna vaccines against tumor growth and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0408774A true BRPI0408774A (pt) 2006-03-28

Family

ID=33434911

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408774-7A BRPI0408774A (pt) 2003-03-24 2004-03-24 vacinas de dna contra crescimento tumoral e seus usos

Country Status (18)

Country Link
US (2) US8716254B2 (pt)
EP (1) EP1622648B1 (pt)
JP (1) JP4616827B2 (pt)
KR (1) KR101199789B1 (pt)
CN (1) CN1791433B (pt)
AT (1) ATE472339T1 (pt)
AU (1) AU2004236636B2 (pt)
BR (1) BRPI0408774A (pt)
CA (1) CA2519953C (pt)
DE (1) DE602004027902D1 (pt)
DK (1) DK1622648T3 (pt)
ES (1) ES2345200T3 (pt)
MX (1) MXPA05010255A (pt)
PL (1) PL1622648T3 (pt)
PT (1) PT1622648E (pt)
RU (1) RU2343195C2 (pt)
WO (1) WO2004099389A2 (pt)
ZA (1) ZA200508579B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
KR100790377B1 (ko) * 2006-02-15 2008-01-02 고려대학교 산학협력단 인터페론감마를 발현하는 살모넬라 균주를 함유하는항바이러스용 조성물
ES2393372T3 (es) * 2006-06-21 2012-12-20 The Scripps Research Institute Composición de ADN contra el antígeno tumoral estromal FAP y métodos de utlización de la misma
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
EP2102234A2 (en) * 2006-11-28 2009-09-23 GHC Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
JP5546448B2 (ja) 2008-03-31 2014-07-09 株式会社バイオイミュランス ＭＨＣクラスＩＩ分子に提示されるサーバイビン（Ｓｕｒｖｉｖｉｎ）の部分ペプチドとその利用法
RU2507253C2 (ru) * 2009-03-27 2014-02-20 Айдгенозише Технише Хохшуле Цюрих Презентируемый в salmonella enterica n-гликан из c. jejuni и его производные
CA2769409A1 (en) * 2009-08-17 2011-02-24 The Penn State Research Foundation Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
CN102210862B (zh) * 2011-06-01 2013-06-12 中国人民解放军南京军区福州总医院 基于Livin的免疫刺激复合物及其制备方法和应用
MX2015011095A (es) * 2013-02-26 2016-03-11 Sloan Kettering Inst Cancer Composiciones y metodos para inmunoterapia.
EP3607974A1 (en) * 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
WO2014163213A1 (en) * 2013-04-05 2014-10-09 Kyushu University, National University Corporation Anti-tumor dna vaccine
EP3016973A1 (en) * 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
EP3116903A2 (en) * 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
MX2017002594A (es) * 2014-08-29 2017-05-19 Univ California Vacuna para sistemas de produccion ganadera.
US10414810B2 (en) 2015-05-07 2019-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Double mutant survivin vaccine
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
CN108368176B (zh) 2015-10-01 2022-06-07 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
WO2018147801A1 (en) * 2017-02-07 2018-08-16 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
RU2770490C1 (ru) * 2021-07-14 2022-04-18 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" Рекомбинантная плазмидная ДНК pET19b-Surv-OL, обеспечивающая синтез гибридного белка сурвивин-обелин (Surv-OL) и гибридный белок, связываемый анти-сурвивин антителами и обладающий биолюминесцентной активностью
CN116077534A (zh) * 2023-01-31 2023-05-09 大连工业大学 一种凝结芽孢杆菌的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) * 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US5733760A (en) * 1994-08-05 1998-03-31 Virus Research Institute Salmonella vectors encoding truncated pag fusion protein, method of making, and uses thereof
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
AU736587B2 (en) * 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
JP2001515052A (ja) * 1997-08-13 2001-09-18 ザ ユーエイビー リサーチ ファンデーション 遺伝子ベクターの局所施用によるワクチン接種
ATE305510T1 (de) * 1997-12-17 2005-10-15 Immunex Corp Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
US20030215803A1 (en) * 2000-12-07 2003-11-20 Garcia Pablo Dominguez Human genes and gene expression products isolated from human prostate
WO2000003693A1 (en) * 1998-07-14 2000-01-27 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
IT1303683B1 (it) * 1998-10-30 2001-02-23 Menarini Ricerche Spa Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
BR9916315A (pt) * 1998-12-18 2001-08-14 Haarmann & Reimer Gmbh Preparados de aroma e/ou perfumes encapsulados
WO2002002622A2 (en) * 2000-06-29 2002-01-10 The Salk Institute For Biological Studies Crystal structure of survivin
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
CA2500661A1 (en) * 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
EP1572736A2 (en) * 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation

Also Published As

Publication number Publication date
PL1622648T3 (pl) 2010-11-30
US8716254B2 (en) 2014-05-06
ZA200508579B (en) 2007-04-25
CN1791433A (zh) 2006-06-21
WO2004099389A2 (en) 2004-11-18
ATE472339T1 (de) 2010-07-15
DE602004027902D1 (de) 2010-08-12
WO2004099389A3 (en) 2005-09-29
RU2343195C2 (ru) 2009-01-10
MXPA05010255A (es) 2005-12-14
CA2519953A1 (en) 2004-11-18
KR20050121694A (ko) 2005-12-27
EP1622648A2 (en) 2006-02-08
CA2519953C (en) 2016-01-05
EP1622648B1 (en) 2010-06-30
RU2005132578A (ru) 2006-05-10
EP1622648A4 (en) 2007-02-14
US20140322249A1 (en) 2014-10-30
DK1622648T3 (da) 2010-09-06
JP2006523217A (ja) 2006-10-12
AU2004236636A1 (en) 2004-11-18
ES2345200T3 (es) 2010-09-17
US20040192631A1 (en) 2004-09-30
CN1791433B (zh) 2010-05-26
US9655815B2 (en) 2017-05-23
JP4616827B2 (ja) 2011-01-19
PT1622648E (pt) 2010-08-31
KR101199789B1 (ko) 2012-11-09
AU2004236636B2 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
BRPI0408774A (pt) vacinas de dna contra crescimento tumoral e seus usos
Finn et al. Prophylactic cancer vaccines
Chiang et al. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines
Seledtsov et al. Clinically feasible approaches to potentiating cancer cell-based immunotherapies
Lollini et al. Vaccines for tumour prevention
ES2328025T3 (es) Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
Grauer et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma model
McDonald et al. Synthetic self-adjuvanting glycopeptide cancer vaccines
KR20140083987A (ko) 효모-muc1 면역요법 조성물 및 그 용도
EA201000209A1 (ru) Новая иммунотерапия против нейрональных опухолей и опухолей головного мозга
ES2460899T3 (es) Inmunoterapia basada en células cancerosas alógenas
Bolesta et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery
CN109073637A (zh) 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
JP2018508533A (ja) 方法
Kim et al. A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells
Lopes et al. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
ES2357548T3 (es) Péptido poli-epitope derivado de timidilato sintasa que tiene actividad inmunológica y antitumoral.
Nelson et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’tumor-associated antigen, neu in a rat mammary tumor model
Hosseinzadeh et al. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers
Bae et al. Photodynamic therapy‐generated tumor cell lysates with CpG‐oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells
EP2804626B1 (en) Autologous cancer cell vaccine
Chen et al. Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
Barr et al. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL